1
3
4
News & Events
InterVenn Demonstrates Power of Its GlycoVision™ Platform
May 8, 2023
GlycoVision achieved high sensitivity and specificity in predicting advanced adenoma and colorectal cancer. Read more
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates
March 7, 2022
Company outlines its pipeline strategy and R&D progress for crop protection and plant delivery innovations. Read more
Foghorn Therapeutics Highlights Recent Clinical and Research Progress
January 9, 2023
Also announced strategic objectives for 2023. Read more
6
7
News & Events
InterVenn Demonstrates Power of Its GlycoVision™ Platform
May 8, 2023
GlycoVision achieved high sensitivity and specificity in predicting advanced adenoma and colorectal cancer. Read more
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates
March 7, 2022
Company outlines its pipeline strategy and R&D progress for crop protection and plant delivery innovations. Read more
Foghorn Therapeutics Highlights Recent Clinical and Research Progress
January 9, 2023
Also announced strategic objectives for 2023. Read more
14
Championing
collaborations
that improve health
and the quality of life
for everyone.

#JoinForces
#LifeSciencesInTheFuture
21
25
29
35
37
News & Events
InterVenn Demonstrates Power of Its GlycoVision™ Platform
May 8, 2023
GlycoVision achieved high sensitivity and specificity in predicting advanced adenoma and colorectal cancer. Read more
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates
March 7, 2022
Company outlines its pipeline strategy and R&D progress for crop protection and plant delivery innovations. Read more
Foghorn Therapeutics Highlights Recent Clinical and Research Progress
January 9, 2023
Also announced strategic objectives for 2023. Read more
39
41